Literature DB >> 23341634

Fas expression by tumor stroma is required for cancer eradication.

Joanna J Listopad1, Thomas Kammertoens, Kathleen Anders, Bjoern Silkenstedt, Gerald Willimsky, Karin Schmidt, Anja A Kuehl, Christoph Loddenkemper, Thomas Blankenstein.   

Abstract

The contribution of molecules such as perforin, IFN-γ (IFNγ), and particularly Fas ligand (FasL) by transferred CD8(+) effector T (T(E)) cells to rejection of large, established tumors is incompletely understood. Efficient attack against large tumors carrying a surrogate tumor antigen (mimicking a "passenger" mutation) by T(E) cells requires action of IFNγ on tumor stroma cells to avoid selection of antigen-loss variants. Because "cancer-driving" antigens (CDAs) are rarely counterselected, IFNγ may be expected to be dispensable in elimination of cancers by targeting a CDA. Here, initial regression of large, established tumors required neither IFNγ, FasL, nor perforin by transferred CD8(+) T(E) cells targeting Simian Virus (SV) 40 large T as CDA. However, cytotoxic T(E) cells lacking IFNγ or FasL could not prevent relapse despite retention of the rejection antigen by the cancer cells. Complete tumor rejection required IFNγ-regulated Fas by the tumor stroma. Therefore, T(E) cells lacking IFNγ or FasL cannot prevent progression of antigenic cancer because the tumor stroma escapes destruction if its Fas expression is down-regulated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23341634      PMCID: PMC3568383          DOI: 10.1073/pnas.1218295110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  A cancer immunosurveillance controversy.

Authors:  Zhihai Qin; Thomas Blankenstein
Journal:  Nat Immunol       Date:  2004-01       Impact factor: 25.606

2.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 3.  Tumor antigens.

Authors:  J L Urban; H Schreiber
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

4.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

Review 5.  Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Authors:  Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber
Journal:  Hematol Oncol Clin North Am       Date:  2006-06       Impact factor: 3.722

6.  CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications.

Authors:  Anne Janin; Christophe Deschaumes; Marjan Daneshpouy; Jérôme Estaquier; Juliette Micic-Polianski; Premavathy Rajagopalan-Levasseur; Khadija Akarid; Nicolas Mounier; Eliane Gluckman; Gérard Socié; Jean Claude Ameisen
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

7.  Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Authors:  Kathleen Anders; Christian Buschow; Andreas Herrmann; Ana Milojkovic; Christoph Loddenkemper; Thomas Kammertoens; Peter Daniel; Hua Yu; Jehad Charo; Thomas Blankenstein
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more
  21 in total

Review 1.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

2.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

Review 3.  Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors:  M D Kumar; A Dravid; A Kumar; D Sen
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

4.  Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Authors:  Nicolas Acquavella; David Clever; Zhiya Yu; Melody Roelke-Parker; Douglas C Palmer; Liqiang Xi; Holger Pflicke; Yun Ji; Alena Gros; Ken-Ichi Hanada; Ian S Goldlust; Gautam U Mehta; Christopher A Klebanoff; Joseph G Crompton; Madhusudhanan Sukumar; James J Morrow; Zulmarie Franco; Luca Gattinoni; Hui Liu; Ena Wang; Francesco Marincola; David F Stroncek; Chyi-Chia R Lee; Mark Raffeld; Marcus W Bosenberg; Rahul Roychoudhuri; Nicholas P Restifo
Journal:  Cancer Immunol Res       Date:  2014-10-30       Impact factor: 11.151

5.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

Review 6.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

7.  CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Authors:  Julie Leignadier; Stephanie Favre; Sanjiv A Luther; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2015-09-11       Impact factor: 8.110

8.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

9.  DICE: A novel tumor surveillance mechanism-a new therapy for cancer?

Authors:  Marcus E Peter
Journal:  Cell Cycle       Date:  2014-04-01       Impact factor: 4.534

Review 10.  CD8+ T cell differentiation and dysfunction in cancer.

Authors:  Mary Philip; Andrea Schietinger
Journal:  Nat Rev Immunol       Date:  2021-07-12       Impact factor: 108.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.